SCIENTIFIC **Reports**

Received: 07 January 2016 Accepted: 01 April 2016 Published: 22 April 2016

OPEN Neutrophil Elastase-mediated proteolysis activates the antiinflammatory cytokine IL-36 **Receptor antagonist**

Tom Macleod^{1,*}, Rosella Doble^{1,*}, Dennis McGonagle^{2,3}, Christopher W. Wasson¹, Adewonuola Alase², Martin Stacey^{1,‡} & Miriam Wittmann^{2,3,4,‡}

The interleukin-36 receptor antagonist (IL-36Ra) which regulates IL-36 α , - β and - γ is linked to psoriatic inflammation, especially loss-of-function mutations in pustular psoriasis subtypes. As observed with other IL-1 superfamily proteins, the IL-36 members require N-terminal cleavage for full biological activity but the mechanisms of IL-36Ra activation remain poorly defined. Using different blood leukocyte and skin resident cell preparations, and recombinant proteins, we have identified that neutrophil elastase, but not other neutrophil derived proteases, cleaves IL-36Ra into its highly active antagonistic form. The activity of this processed form of IL-36Ra was confirmed in human primary dermal fibroblasts and keratinocytes and in skin equivalents. A significant dose dependent reduction of IL-36 γ induced IL-8 and chemokine ligand 20 (CCL20) levels were detected following addition of the cleaved IL-36Ra compared to full length IL-36Ra. By activating IL-36Ra, the neutrophil derived protease can inhibit IL-36 induced chemokine production, including IL-8 and CCL20, and reduce further inflammatory cell infiltration. These findings strongly indicate neutrophil elastase to be a key enzyme in the biological function of IL-36Ra and that neutrophils can play a regulatory role in psoriatic inflammation with regard to balancing the pro-inflammatory activity of IL-36.

Psoriasis is an immune-mediated inflammatory disease affecting approximately 2% of the Caucasian population¹. Psoriatic inflammation ranges broadly in both form and severity, presenting as localised plaques, arthritis, pustular lesions or systemic inflammatory outbreaks². Psoriasis is characterised by hyperkeratotic plaques with increased capillary networks in the upper dermis, accompanied by epidermal inflammatory cell infiltrates, culminating in lesions with a raised red and scaly appearance.

Despite the documented role that T cells and the adaptive immune system play in psoriasis, recent research has established a crucial role for the innate inflammatory mediators, including IL-1 family members, tumour necrosis factor α (TNF α), IL-12, IL-23, IL-17C and IL-20 family members in initiating and maintaining psoriatic inflammation^{3,4}. Examination of mRNA and protein has revealed the IL-36 cytokines to be amongst the most highly up-regulated and disease specific genes expressed in psoriatic plaques⁵. The IL-36 cytokines are members of the IL-1 super-family, consisting of the agonists IL-36 α , IL-36 β and IL-36 γ , and an antagonist IL-36Ra. Analogous to other members of the IL-1 family, the agonists bind a specific receptor (IL-36R), causing recruitment of IL-1 receptor accessory protein (IL-1RAcP) to facilitate signal transduction via myeloid differentiation 88 (MyD88) and TNF receptor-associated factor 6 (TRAF6), ultimately resulting in activation of the nuclear factor NF-KB and expression of a host of pro-inflammatory mediators⁶. The receptor antagonist (IL-36Ra) binds the same IL-36R but does not lead to accessory protein recruitment and the consequent signalling, thereby competing with and inhibiting the activity of the other IL-36 cytokines⁷. Overexpression of IL-36 α in keratinocytes of K14-IL-36\alpha transgenic mice leads to the development of transient inflammatory skin symptoms in mice, and leaves them highly susceptible to development of psoriatic-like plaques upon treatment with

¹School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK. ²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, UK. ³National Institute of Health Research (NIHR) LMBRU, Chapel Allerton Hospital, Leeds. ⁴Centre for Skin Sciences, Faculty of Life Sciences, University of Bradford, UK. *These authors contributed equally to this work. *These authors jointly supervised this work. Correspondence and requests for materials should be addressed to M.W. (email: M.Wittmann@leeds.ac.uk)

12-O-tetradecanoylphorol-13-acetate. Indeed, eluding towards the potential importance of the IL-36 family in psoriasis, these mice act identically on a Rag2^{-/-} background where there are no T cells to affect the development of the plaques. Using the same model, IL-36Ra deficient mice exhibited chronic skin abnormalities and exacerbated plaque development, demonstrating the importance of IL-36Ra in the regulation of IL-36 mediated inflammation⁸. Of pivotal importance is the observation that mutations of *IL36-RN* (gene encoding IL-36Ra) have also been shown to cause generalised pustular psoriasis (GPP), the most severe and potentially life threatening form of psoriatic inflammation⁹.

Like IL-1 and other members of the IL-1 family the activity of IL-36 cytokines is strictly regulated through the N-terminal cleavage of the nascent peptides. Although the active forms of the cytokines have not yet been isolated *in vivo*, it has been demonstrated that precise cleavage 9 amino acids upstream of a common A-X-D motif is crucial for activation. In the case of IL-36Ra, this is achieved by removal of the N-terminal methionine, generating the active IL-36Ra V2 form of the protein possessing an N-terminal valine residue⁷. Recent crystallographic data reveal that without this stringent cleavage, it's likely that N-terminal overhang interferes with receptor binding¹⁰. However, unlike others of the IL-1 family, the IL-36 proteins contain no caspase-1 cleavage motif, and the amino acid sequence surrounding the cleavage sites bear little homology to one another.

As a result, despite understanding where cleavage must occur, the responsible physiological proteases have remained elusive. It has been postulated before that as the sequences surrounding the cleavage sites are markedly different, a number of different proteases may be responsible for their cleavage. The activity of these proteases may therefore be critical in regulating the physiological and pathological roles of the IL-36 cytokines. Through the use of proteases derived from cells present at psoriatic lesions we show that neutrophil elastase is capable of cleaving IL-36Ra into its mature anti-inflammatory form. Given that a balance must exist between elastase and its inhibitors, it seems logical that disturbances in such a balance might influence the ratio of active to inactive IL-36Ra and hence may be exploited to effect the regulation of IL-36 mediated inflammation.

Results

Polymorphonuclear cell supernatant cleaves IL-36Ra. IL-36 cytokines are expressed in the skin, lungs and joints, and since the skin is the primary site of psoriasis it seemed logical that IL-36 proteins may be cleaved to their active forms in the skin compartment, and that therefore a protease cleaving the proteins to full activity would also be expressed here. Small Ubiquitin-like Modifier (SUMO) tagged IL-36Ra was therefore incubated with supernatants from fibroblasts, keratinocytes and polymorphonuclear cells (PMNs); all cells expected to be found in lesional psoriatic skin. Western blot (WB) analysis showed supernatant from PMNs stimulated with phorbol myristate acetate (PMA) cleaved IL-36Ra, whilst in this experimental setup no cleavage was evident from incubations with fibroblast or keratinocyte derived supernatants (Fig. 1).

A serine protease is responsible for the cleavage of IL-36Ra. As PMN supernatant was shown to cleave IL-36Ra, further incubations with stimulated PMN supernatant were performed to reduce the number of candidate proteases. Incubating in the presence or absence of pan-protease inhibitors (1x PI Roche), phenylmethanesulfonylfluoride (PMSF) (1 mM), iodoacetic Acid (IAA) (1 μ M), ethylenediaminetetraacetic acid (EDTA) (500 μ M) and α 1 anti-trypsin (1 mg/ml) was used to identify which protease family the active protease belongs to. WB analysis of incubations revealed that in the presence of IAA and EDTA, inhibitors of cysteine and metalloproteinase proteases, cleavage occurred. However, incubation with PMSF and α 1 anti-trypsin, prevented processing indicating that the cleavage was due to a serine protease (Fig. 2).

Neutrophil elastase cleaves IL-36Ra to its mature IL-36Ra V2 form. Since a PMN serine protease was identified to cleave IL-36Ra, the SUMO tagged protein was incubated with a number of recombinant serine proteases expressed by neutrophils. Incubations were performed with cathepsin G, neutrophil elastase, and proteinase 3 at a ratio of 1:100 protease to protein. Analysis of the incubations by SDS-PAGE indicated that neutrophil elastase efficiently cleaved IL-36Ra, compared to proteinase 3 and cathepsin G which had much lower cleavage activity (Fig. 3). Further analysis of the cleaved products by mass spectrometry and N-terminal sequencing identified the truncations generated (shown in table 1) and revealed that elastase cleaved IL-36Ra precisely 9 amino acids upstream of its A-X-D motif to the mature IL-36Ra V2 form, whilst prolonged incubation with cathepsin G and proteinase 3 generated a cleavage product with an N-terminal serine (IL-36Ra S4). In order to show these truncations were not the product of fusion protein artefacts, identical incubations using full length proteins lacking N-terminal SUMO tags were performed. These generated the same cleavage products (results not shown).

IL-36Ra V2 regulates IL-36 mediated inflammation in primary fibroblasts and keratinocytes and an epidermal skin model. To compare the antagonistic properties of full length IL-36Ra and the mature form generated by elastase cleavage, primary fibroblasts and keratinocytes were treated with various concentrations of full length IL-36Ra, IL-36Ra S4 and IL-36Ra V2 30 minutes prior to stimulation with IL-36 agonist. Neither full length IL-36Ra nor IL-36Ra S4 had any noticeable antagonistic activity on the agonist control. IL-36Ra V2, however, generated a significant reduction in IL-8 production in both fibroblasts (Fig. 4A) and keratinocytes (Fig. 4B) when compared to the agonist control that followed a dose dependent pattern down to a concentration of 1 nM (Supplementary Fig S1). For all experiments boiled controls were performed for IL-36Ra V2 and IL-36Ra S4 on the basis of which we ruled out any LPS contamination. None of the IL-36Ra preparations showed cytokine inducing activity when given alone.

In addition to testing the effects of full length and mature antagonists on monolayer primary cells, their biological functions were also examined in an epidermal skin model. Skin equivalents were incubated with IL-36 agonist with or without the presence of either full length or active IL-36Ra from day 10 for 96 hours. In both



Figure 1. SUMO tagged IL-36Ra cleavage by activated cellular supernatants. SUMO tagged IL-36Ra was incubated with a range of supernatants from activated cells. PMNs were isolated from whole blood of healthy donors and then stimulated with 100 ng/ml of PMA for 1 hour at 37 °C. Human primary keratinocytes and fibroblasts were stimulated with 100 ng/ml of PMA for 24 hours at 37 °C. Supernatants were removed from the cells and incubated with IL-36Ra for 1 hour at 37 °C, along with a PBS control. Samples were subjected to WB analysis.



Figure 2. IL-36Ra cleavage by activated PMN supernatant is prevented by serine protease inhibitors. SUMO tagged IL-36Ra was incubated with supernatant from PMNs stimulated with PMA for 1 hour at 37 °C. Incubation was performed in the presence or absence of a range of protease inhibitors. PI = complete protease inhibitor cocktail (Roche), EDTA = Ethylenediaminetetraacetic acid, inhibitor of proteases where a metal ion is required for cleavage, PI Roche = complete ultra-protease inhibitor, PMSF = phenylmethylsulfonyl fluoride a pan serine protease inhibitor, α 1 anti-trypsin is another pan serine protease inhibitor. Samples were then analysed using WB.

monolayer cultures and skin equivalents, full length IL-36Ra exhibited no antagonistic activity, whilst the IL-36Ra V2 truncation antagonised IL-36 agonist stimulation causing a significant reduction in both IL-8 and CCL20 expression (Fig. 4C). These data suggest a role for elastase in activating IL-36Ra and the consequent regulation of IL-36 mediated inflammation.

Incubation with the recombinant proteases generated two forms of IL-36Ra; the established active IL-36Ra V2 and to a lesser extent the smaller IL-36Ra S4. IL-36Ra S4 was also tested alongside IL-36Ra V2 to see if any biological function could be observed. Whilst IL-36Ra V2 acted as predicted, IL-36Ra S4 did not inhibit IL-36 agonist





IL-36RA	Elastase	Proteinase 3	Cathepsin G	PMN SN
V2	x			
L3				х
S4		x	x	х

Table 1. Summary of cleavage products identified by mass spectrometry and N-terminal sequencing. Depicted are all the cleavage products identified by mass spectrometry and N-terminal sequencing following incubation with recombinant serine proteases (elastase, proteinase 3 and cathepsin G) as well as with activated PMN supernatant (PMN SN). The IL-36 cleavage products are named by the new N-terminal amino acid after cleavage.

mediated expression of IL-8, thus exhibits no antagonistic activity (Fig. 4A,B). This suggests further cleavage of IL-36Ra from the V2 to the S4 form deactivates the antagonist.

Discussion

Given the high expression and importance of IL-36 activity in psoriatic inflammation, understanding the mechanisms of its regulation is an important step towards a targeted therapy^{5,11}. The IL-36 cytokines contribute to inflammatory signalling primarily in the skin, lungs and joint tissue through activation of NF-κB, and are increasingly recognised as having a protective role in anti-fungal immune responses. Like other IL-1 family members, IL-36 cytokines have been shown to require N-terminal cleavage precisely 9 amino acids upstream of a shared A-X-D motif⁷. Proteases responsible for cleavage of the proteins have proved elusive due in part to the lack of shared amino acid consensus surrounding the cleavage sites. Despite this, several neutrophil proteases have recently been identified as capable of cleaving and activating IL-36 agonists¹². Our study has shown that a neutrophil protease is also capable of activating IL-36 receptor antagonist. We have shown that neutrophil elastase cleaves the receptor antagonist member of the IL-36 cytokines, IL-36Ra, 9 amino acids upstream of its A-X-D consensus, generating IL-36Ra V2; a biologically active form of the antagonist.

With regard to neutrophil-mediated cleavage of IL-36Ra, these data bring to light some intriguing insights into the effect neutrophils may have on IL-36 mediated inflammation. Incubation with neutrophil proteases revealed that neutrophil elastase efficiently cleaved the majority of IL-36Ra to its active IL-36Ra V2 truncation whilst prolonged incubation with cathepsin G and proteinase 3 lead to a small percentage of the antagonist being cleaved to an inactive IL-36Ra S4 truncation. The ability of neutrophil elastase to activate IL-36Ra suggests infiltrating neutrophils might promote regulation of IL-36 mediated inflammation through the production of elastase. IL-36 agonists promote the maturation of human dendritic cells and their production of inflammatory mediators and enhancement of CD4 T cell effector functions and therefore have a far-reaching influence¹³. The lack of antagonistic regulation would perpetuate a positive feedback loop whereby active IL-36 agonists stimulate dendritic



Figure 4. IL-36Ra requires removal of the N-terminal methionine to enable antagonistic activity. Human primary fibroblasts or keratinocytes were treated with IL-36Ra V2 and IL-36Ra S4 in the presence of IL-36 agonist (10 nM). After 48 hours of treatment IL-8 concentrations analysed by ELISA. (A) Fibroblasts were stimulated with IL-36Ra V2 or IL-36Ra S4 in the presence of IL-36 agonist, n = 4. (B) Keratinocytes were stimulated with IL-36Ra V2 or IL-36Ra S4 in the presence of active IL-36 agonist. n = 4. Mean +/- SEM is depicted on all graphs. NS = non-stimulated, FL = full length. (C) EpiSkin epidermal skin rafts were treated on day 11 with full length IL-36Ra or IL-36Ra V2 at 100 nM in the presence of IL-36 agonist (100 nM). After 96 hours of treatment, IL-8 and CCL20 concentrations were analysed by ELISA. n = 2.

cells, fibroblasts and keratinocytes to express CCL20, IL-8, IL-12, IL-17C, TNF α , and more IL-36^{14–17}, which in turn reinforce the inflammatory environment that may give rise to generation of psoriatic plaque lesions. These data suggest infiltrating neutrophils may favour cleavage of IL-36Ra to the active V2 form, placing a dampener on the self-perpetuating feedback loop to allow a more regulatory environment to exist.

In addition to their role in psoriatic inflammation the epithelial derived IL-36 cytokines have been implicated in lung pathology and shown to affect the activity of numerous immune cells. Bronchial epithelial cells strongly induce IL-36 when challenged with cigarette smoke and in response to infectious agents including Rhinovirus and Pseudomomonas aeruginosa¹⁸⁻²⁰. Moreover mouse models have shown that administration of IL-36 leads to neutrophilic infiltrate into the bronchial alveolar fluid²¹. IL-36 agonists and IL-36Ra are also expressed in response to the respiratory fungal pathogen Aspergillus fumigatus suggesting a role in antifungal immunity²². Both IL-36 γ and IL-36Ra are found to be significantly induced when incubating live A. fumigatus conidia and hyphae with peripheral blood mononuclear cells, and IL-36Ra expression continues to be induced by heat-killed conidia. It has also been shown that blocking the IL-36 receptor pathway by IL-36Ra in A. fumigatus infection causes a reduction in IL-17 and interferon- γ (IFN γ) expression; cytokines well established as important antifungal inflammatory mediators²². Neutrophils play a vital role in fungal immunity where a strong neutrophil response is paramount to resolution of infection. However, in addition to their phagocytic role, the neutrophils may simultaneously act in a regulatory capacity by activating local IL-36Ra, keeping IL-36 mediated inflammation in check. Furthermore, since IL-36Ra alone is induced by heat-killed conidia, neutrophils present at the latter stages of Aspergillus infection, where Aspergillus debris may induce IL-36Ra expression, may promote resolution of inflammation through elastase mediated activation of IL-36Ra.

Whilst IL-36Ra may also be activated by an intracellular mechanism analogous to IL-1 β processing, there have been multiple documented examples of IL-1 family members becoming activated by extracellular neutrophil proteases after release of their pro-forms. Within the inflammatory environment, many cells will undergo pyroptosis and necrosis where cell swelling and membrane rupture results in the release of unprocessed IL-1 family

members exposing them to extracellular proteases. Numerous neutrophil proteases have been shown to process and activate IL-1 α , IL-1 β , and IL-33. IL-1 α has been shown to be processed and activated by neutrophil proteases with a comparable efficiency to that of calpain and granzyme B, and is detectable in bronchoalveolar lavage fluids from patients with cystic fibrosis²³. Both neutrophil elastase and cathepsin G have been shown to cleave and activate IL-1 β , albeit to a lesser extent than caspase-1, yet disease progression of neutrophil-dominated forms of arthritis in *Casp1^{-/-}* is comparable to that in wild type mice, suggesting a functional role for other enzymes in the regulation of IL-1 β^{24-26} . Neutrophil elastase and cathepsin G also cleave and activate extracellular IL-33 to an extent that is detectable in bronchoalveolar lavage fluid from mice with neutrophil-dominated acute lung injury²⁷. Neutrophil elastase activation of IL-36Ra may therefore be of importance in an inflammatory context, where unprocessed IL-36Ra may be released via pyroptosis and activated by infiltrating neutrophils.

Understanding that neutrophils may activate IL-36Ra via neutrophil elastase gives spectrum for manipulating IL-36Ra activity and hence IL-36 mediated inflammation, at either the cellular or molecular level. This may potentially yield an area where therapeutic intervention might be possible. However, due to a lack of appropriate reagents important questions still remain unanswered. The ratio of active to inactive IL-36 and IL-36Ra in healthy and diseased tissue is unknown. It is also unclear whether extracellular availability of IL-36Ra or excessive protease cleavage are limiting factors in the resolution of inflammation. These data also raise the question as to why, if neutrophils activate IL-36Ra, there is such unchecked IL-36-mediated inflammation in psoriasis when psoriatic lesions are well characterised to have increased infiltration of neutrophils. In order to answer these important questions better IL-36 protein detecting reagents distinguishing between the active and inactive forms need to be developed.

Materials & Methods

Generation of IL-36 proteins. Constructs of full length IL-36Ra, IL-36Ra V2, IL-36Ra S4 and IL-36 γ S18 with N-terminal SUMO tags were generated and expressed in *BL21 (DE3) E. coli*. Protein for use in cleavage assays was purified by Ni²⁺-affinity chromatography and size exclusion chromatography. Proteins used for stimulations were purified by Ni²⁺-affinity chromatography prior to cleavage of N-terminal SUMO by the Ulp1 protease, followed by further ion exchange and size exclusion chromatography.

Cell culture and stimulations. Primary fibroblasts, keratinocytes and neutrophils were cultured in DMEM (GE Healthcare), KGM-2 (PromoCell) and RPMI (Gibco) respectively. In order to produce supernatant for cleavage assays, cells were grown in serum free media or Opti-MEM (Gibco) to avoid inhibition of any active proteases. Immediately after isolation, neutrophils were stimulated with 100 ng/ml PMA for 1 hour at 37 °C prior to removing cells by centrifugation and harvesting supernatant. For analysis of IL-36Ra's antagonistic capabilities, fibroblasts and keratinocytes grown to 70% confluence in DMEM or KGM-2 minus EGF and hydrocortisone were stimulated with IL-36 γ S18 15 minutes after addition of IL-36Ra. Supernatants were harvested 48 hours after stimulation for analysis by ELISA.

Skin equivalents. Epidermal skin equivalents (EpiSkin) were purchased from SkinEthics and maintained according to the manufacturer's protocol. Skin equivalents were treated on day 11 with either full length or active IL-36Ra with or without IL-36 γ S18 for 96 hours. Supernatants were harvested on day 15 for analysis of IL-8 and CCL20 expression measured by ELISA.

Cleavage assays, SDS PAGE and western blotting. $1-2 \mu g$ of SUMO tagged IL-36Ra were incubated with supernatants from primary cells at 37 °C for 1 hour with or without protease inhibitors (IAA 50 μ M), EDTA (500 μ M), PMSF (1 mM), 1x PI Roche, α 1 anti-trypsin (1 mg/ml) were used at concentrations outlined by the manufacturers. Incubations performed with recombinant proteases (proteinase 3, human neutrophil elastase, cathepsin G (Calbiochem)) were set up as recommended by manufacturers and incubated at 37 °C for up to 5 hours. Cleavage was analysed by SDS PAGE or WB using monoclonal anti-IL-36Ra antibody (R&D systems). Cleaved products were further analysed by in-house Liquid Chromatography Mass Spectrometry or analysed via N-terminal sequencing.

Enzyme-linked Immuno-Sorbent Assay. Supernatants collected from stimulated cells were tested for concentrations of IL-8 and CCL20 by ELISA kits from BioLegend and R&D system, respectively. ELISAs were carried out according to protocols provided by the manufacturers.

Statistical analysis. Statistical significance was determined using repeated measures one way ANOVA and Tukey's multiple comparisons test using GraphPad Prism software (GraphPad Software Inc. La Jolla, CA, USA). All data are expressed as means \pm SEM. n represents independent experiments with cells from different donors. **denotes p < 0.001; ***denotes p < 0.0001.

Ethics. All human samples were taken in accordance with the Declaration of Helsinki and participants gave their written informed consent (REC number: 11/YH/0368). All experimental protocol, method and recruitment of healthy volunteers were carried out based on ethical approval by the University of Leeds (BIOSCI09-001). Participating volunteers gave their written informed consent.

References

1. Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis. N Engl J Med. 361, 496-509 (2009).

2. Azfar, R. S. & Gelfand, J. M. Psoriasis and metabolic disease: epidemiology and pathophysiology. *Curr Opin Rheumatol.* **20**, 416–422 (2008).

- 3. Chan, J. R. *et al.* IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. *J Exp Med.* 203, 2577–2587 (2006).
- 4. Ma, H. L. et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 118, 597-607 (2008).
- 5. D'Erme, A. M. et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol. 135, 1025-1032 (2015).
- Towne, J. E., Garka, K. E., Renshaw, B. R., Virca, G. D. & Sims, J. E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 279, 13677–13688 (2004).
- Towne, J. E. *et al.* Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. *J Biol Chem.* 286, 42594–42602 (2011).
- Blumberg, H. et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 204, 2603–2614 (2007).
- 9. Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 365, 620–628 (2011).
- Gunther, S. & Sundberg, E. J. Molecular Determinants of Agonist and Antagonist Signaling through the IL-36 Receptor. *J Immunol.* 193, 921–930 (2014).
- 11. Farooq, M. *et al.* Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. *Hum Mutat.* **34**, 176–183 (2013).
- 12. Henry, C. M. et al. Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines. Cell Rep. 14, 708–722 (2016).
- 13. Vigne, S. et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 118, 5813-5823 (2011).
- 14. Foster, A. M. *et al.* IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin. J Immunol. **192**, 6053–6061 (2014).
- 15. Carrier, Y. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 131, 2428–2437 (2011).
- Mutamba, S., Allison, A., Mahida, Y., Barrow, P. & Foster, N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. *Eur J Immunol.* 42, 607–617 (2012).
- Friedrich, M., Tillack, C., Wollenberg, A., Schauber, J. & Brand, S. IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. *Inflamm Bowel Dis.* 20, 1891–1901 (2014).
- Parsanejad, R., Fields, W. R., Steichen, T. J., Bombick, B. R. & Doolittle, D. J. Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. *J Interferon Cytokine Res.* 28, 703–712 (2008).
- Bochkov, Y. A. *et al.* Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. *Mucosal Immunol.* 3, 69–80 (2010).
- Vos, J. B. et al. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics. 21, 324–336 (2005).
- Ramadas, R. A., Ewart, S. L., Iwakura, Y., Medoff, B. D. & LeVine, A. M. IL-36alpha exerts pro-inflammatory effects in the lungs of mice. Plos One. 7, e45784 (2012).
- Gresnigt, M. S. et al. The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 43, 416–426 (2013).
- Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell. 44, 265–278 (2011).
- 24. Black, R. A. *et al.* Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. *J Biol Chem.* **263**, 9437–9442 (1988).
- Hazuda, D. J., Strickler, J., Kueppers, F., Simon, P. L. & Young, P. R. Processing of precursor interleukin 1 beta and inflammatory disease. J Biol Chem. 265, 6318–6322 (1990).
- Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 60, 3651–3662 (2009).
- 27. Lefrancais, E. *et al.* IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. *Proc Natl Acad Sci USA* **109**, 1673–1678 (2012).

Acknowledgements

This work was supported by the Leeds Foundation for Dermatological Research, BSF grant 5035 and MRC (MR/ M01942X/1).

Author Contributions

T.M. and R.D. conducted experiments for IL-36 molecule expression, cell culture and protease related experiments. T.M. contributed to data analysis and writing of the manuscript. A.A. contributed to keratinocyte and fibroblast culture and experiments. M.W. contributed to setup and planning, analysis of the IL-36 experiments and writing of the manuscript. M.S. contributed to IL-36 experiment planning, planning and analysis of IL-36 cleavage and expression experiments and manuscript writing. C.W.W. contributed to experiments with skin equivalents. D.M. contributed to experimental planning and critical discussion of results and the manuscript. All authors read and reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Macleod, T. *et al.* Neutrophil Elastase-mediated proteolysis activates the antiinflammatory cytokine IL-36 Receptor antagonist. *Sci. Rep.* **6**, 24880; doi: 10.1038/srep24880 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/